Cited by 18Bone health and osteoporosis researchHIV-related health complications and treatmentsDiabetes, Cardiovascular Risks, and Lipoproteins

More rapid bone mineral density loss in older men with diabetes: the Osteoporotic Fractures in Men (MrOS) study

Open access
Tramontana, Flavia, Napoli, Nicola, Litwack-Harrison, Stephanie, Bauer, Douglas C, Orwoll, Eric S, Cauley, Jane A, Strotmeyer, Elsa S, Schwartz, Ann V·2024·The Journal of Clinical Endocrinology & Metabolism

Abstract

Context Type 2 diabetes mellitus is associated with more rapid bone loss in women, but less evidence is available for men or those with prediabetes. Objective To determine whether bone loss rate is affected by diabetes status in older men, we analyzed data from the Osteoporotic Fractures in Men (MrOS) study. Methods The multisite MrOS study enrolled 5994 men aged ≥ 65 years. Diabetes status was defined by self-report, diabetes medication use, or elevated fasting serum glucose at baseline. Hip bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA) at baseline and a follow-up visit after 4.6 ± 0.4 years. This analysis included 4095 men, excluding those without follow-up DXA or with unknown diabetes status. Changes in hip BMD in participants with normoglycemia (NG), prediabetes, or type 2 diabetes, excluding thiazolidinedione (TZD) users, were evaluated using generalized linear models (GLM). Diabetes medication use and BMD loss among those with type 2 diabetes were also evaluated with GLM. Results In adjusted models, hip BMD loss was greater in men with type 2 diabetes (- 2.23%; 95% CI: -2.54 to -1.91; P Conclusion Men with type 2 diabetes, but not prediabetes, experienced accelerated bone loss compared to participants with normoglycemia. More rapid bone loss predicts increased risk of fractures and mortality in broader populations.

Integrity signals

Registry

Crossref · 10.1210/clinem/dgae045

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sulfonylureas and other insulin secretagogues such as meglitinides are associated with hypoglycemia, bone loss, and fracture risk.

    “Sulfonylureas and other insulin secretagogues such as the meglitinides (repaglinide and nateglinide) are associated with hypoglycemia, bone loss (115), and fracture risk (116) and should be used with caution.”

    From 13. Older Adults: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]

  • Sulfonylureas are associated with hypoglycemia, bone loss, and fracture risk.

    “Sulfonylureas are associated with hypoglycemia, bone loss (121), and fracture risk (122)”

    From 13. Older Adults: Standards of Care in Diabetes—2026 (2026) · cites this paper as [121]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tramontana, F., Napoli, N., Litwack-Harrison, S., Bauer, D. C., Orwoll, E. S., Cauley, J. A., Strotmeyer, E. S., & Schwartz, A. V.
Affiliations
  • Università Campus Bio-Medico (IT)
  • Research Institute, California Pacific Medical Center , San Francisco, CA 94107 ,
  • University of California, San Francisco (US)
  • Oregon Health & Science University (US)
  • University of Pittsburgh (US)
Corresponding author
  • Tramontana, Flavia
  • Napoli, Nicola
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2024-02-26
Volume
109
Issue
12
Pages
e2283-e2290
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4392155012
Cited by
18
References
2
Citations by year
2026: 4 · 2025: 9 · 2024: 5
FWCI
8.02
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Center for Advancing Translational Sciences
  • NIH Roadmap for Medical Research (U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, R01 AG066671, UL1 TR002369)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, prediabetes, bone mineral loss, hip bone loss, older men, osteoporosis, thiazolidinediones, insulin, sulfonylureas, antidiabetic drugs, fracture risk
MeSH terms
Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Osteoporosis, Prediabetic State, Absorptiometry, Photon, Bone Density, Osteoporotic Fractures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review